Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.
For the treatment of osteoarthritis affecting the hip or knee .
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.